Published in Klin Wochenschr on July 15, 1976
In vitro chemosensitivity testing in the treatment of ovarian carcinoma. Arch Gynecol Obstet (1989) 0.81
[In vitro and in vivo sensitivity of animal and human melanomas to various chemotherapeutical agents]. Arch Dermatol Res (1978) 0.75
Detection of induced tumour-resistance to cyclophosphamide by the in vitro short term test. Arch Gynakol (1977) 0.75
Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med (1998) 6.09
Transient neurologic toxicity after hyperbaric subarachnoid anesthesia with 5% lidocaine. Anesth Analg (1993) 4.24
Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study. J Clin Oncol (2002) 2.61
Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status. J Natl Cancer Inst (1996) 2.51
Sulforaphane targets pancreatic tumour-initiating cells by NF-kappaB-induced antiapoptotic signalling. Gut (2008) 2.36
Severe hyperphosphatemia and hypocalcemia caused by bowel preparation for colonoscopy using oral sodium phosphate in end-stage renal disease. Endoscopy (2005) 2.23
Widespread intraspecies cross-contamination of human tumor cell lines arising at source. Int J Cancer (1999) 2.20
Characterization of breast carcinomas by two monoclonal antibodies distinguishing myoepithelial from luminal epithelial cells. J Histochem Cytochem (1986) 2.05
Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet (2015) 2.05
The principal neutralization determinant of simian immunodeficiency virus differs from that of human immunodeficiency virus type 1. Proc Natl Acad Sci U S A (1992) 2.00
In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer: the GEPARTRIO pilot study. Ann Oncol (2005) 1.89
Association of vascular endothelial growth factor expression with intratumoral microvessel density and tumour cell proliferation in human epidermoid lung carcinoma. Br J Cancer (1996) 1.84
VEGF expression by mesenchymal stem cells contributes to angiogenesis in pancreatic carcinoma. Br J Cancer (2008) 1.84
Pathophysiologic basis of contrast enhancement in breast tumors. J Magn Reson Imaging (1999) 1.81
Endocrine treatment options for advanced breast cancer--the role of fulvestrant. Eur J Cancer (2005) 1.65
BioMiner--modeling, analyzing, and visualizing biochemical pathways and networks. Bioinformatics (2002) 1.55
Monoclonal immunoglobulin A antibody directed against serotype-specific epitope of Shigella flexneri lipopolysaccharide protects against murine experimental shigellosis. J Exp Med (1995) 1.54
Multicenter phase II study of oral capecitabine (Xeloda(")) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy. Ann Oncol (2003) 1.53
Prognostic value of vascular endothelial growth factor and its receptor Flt-1 in squamous cell lung cancer. Int J Cancer (1997) 1.51
Pretherapeutic detection of tumour resistance and the results of tumour chemotherapy. Eur J Cancer (1979) 1.49
Cytokine release from placental endothelial cells, a process associated with preterm labour in the absence of intrauterine infection. Cytokine (1999) 1.44
Immunohistochemical detection of the multi-drug-resistance marker P-glycoprotein in uterine cervical carcinomas and normal cervical tissue. Am J Obstet Gynecol (1992) 1.43
Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma. Cancer Res (1997) 1.42
Nitrous oxide is a potent cerebrovasodilator in humans when added to isoflurane. A transcranial Doppler study. Acta Anaesthesiol Scand (1995) 1.40
P-glycoprotein expression in treated and untreated human breast cancer. Br J Cancer (1989) 1.39
Detection of tumor cells in bone marrow of patients with primary breast cancer: a prognostic factor for distant metastasis. J Clin Oncol (1992) 1.32
Beta-galactoside-binding protein secreted by activated T cells inhibits antigen-induced proliferation of T cells. Eur J Immunol (1998) 1.27
Overexpression of P-glycoprotein and glutathione S-transferase-pi in resistant non-small cell lung carcinomas of smokers. Br J Cancer (1991) 1.25
Stable gene silencing of cyclin B1 in tumor cells increases susceptibility to taxol and leads to growth arrest in vivo. Oncogene (2006) 1.24
Augmentation of mechanical properties in osteoporotic vertebral bones--a biomechanical investigation of vertebroplasty efficacy with different bone cements. Eur Spine J (2001) 1.24
[Histologic regression of breast cancer after primary (neoadjuvant) chemotherapy]. Geburtshilfe Frauenheilkd (1994) 1.22
Pegfilgrastim +/- ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study. Ann Oncol (2007) 1.22
Temporal hemodynamic effects of permissive hypercapnia associated with ideal PEEP in ARDS. Am J Respir Crit Care Med (1997) 1.21
HLXB9 activates IL6 in Hodgkin lymphoma cell lines and is regulated by PI3K signalling involving E2F3. Leukemia (2005) 1.21
Comparison of immunohistochemistry and RT-PCR for detection of CD44v-expression, a new prognostic factor in human breast cancer. Int J Cancer (1995) 1.20
Surface protein expression and messenger RNA-splicing analysis of CD44 in uterine cervical cancer and normal cervical epithelium. Cancer Res (1994) 1.19
Differential diagnosis of benign epithelial proliferations and carcinomas of the breast using antibodies to cytokeratins. Hum Pathol (1988) 1.19
Effect of highly active antiretroviral therapy on survival in patients with AIDS-associated pulmonary Kaposi's sarcoma treated with chemotherapy. J Clin Oncol (2001) 1.18
Tissue-factor expression in human non-small-cell lung carcinoma measured by immunohistochemistry: correlation between tissue factor and angiogenesis. Int J Cancer (1998) 1.18
Gene expression of topoisomerase II alpha (TOP2A) by microarray analysis is highly prognostic in estrogen receptor (ER) positive breast cancer. Breast Cancer Res Treat (2008) 1.17
Goserelin depot in the treatment of premenopausal advanced breast cancer. Eur J Cancer (1992) 1.17
The novel c-Met inhibitor cabozantinib overcomes gemcitabine resistance and stem cell signaling in pancreatic cancer. Cell Death Dis (2013) 1.17
Breast cancer patients' expectations in respect of the physician-patient relationship and treatment management results of a survey of 617 patients. Ann Oncol (2007) 1.16
Clinical relevance of predictive tests for cancer chemotherapy. Cancer Treat Rev (1982) 1.16
Prognostic relevance of ploidy, proliferation, and resistance-predictive tests in ovarian carcinoma. Cancer Res (1985) 1.15
Central HER2 IHC and FISH analysis in a trastuzumab (Herceptin) phase II monotherapy study: assessment of test sensitivity and impact of chromosome 17 polysomy. J Clin Pathol (2007) 1.13
The anaesthesia critical incident reporting system: an experience based database. Int J Med Inform (1997) 1.12
Virus-activated CD8 T cells and lymphokine-activated NK cells express the mast cell function-associated antigen, an inhibitory C-type lectin. J Immunol (1998) 1.11
Rational combinations of siRNAs targeting Plk1 with breast cancer drugs. Oncogene (2007) 1.11
A randomised study to compare the effect of the luteinising hormone releasing hormone (LHRH) analogue goserelin with or without tamoxifen in pre- and perimenopausal patients with advanced breast cancer. Eur J Cancer (1995) 1.11
Expression of Fas (CD95/APO-1) and Fas ligand in lung cancer, its prognostic and predictive relevance. Int J Cancer (1999) 1.10
Polo-like kinase: a novel marker of proliferation: correlation with estrogen-receptor expression in human breast cancer. Pathol Res Pract (2000) 1.10
Molecular classification of breast cancer patients by gene expression profiling. J Pathol (2001) 1.08
Depressive action of serum of partially hepatectomized rats on tumour cells in vitro. Eur J Cancer (1967) 1.08
Diagnostic and therapeutic pleuroscopy. Experience with 127 patients. Chest (1980) 1.08
Calcitonin: regional distribution of the hormone and its binding sites in the human brain and pituitary. Proc Natl Acad Sci U S A (1981) 1.06
Tumour induction in the rodent Mastomys natalensis by activation of endogenous papilloma virus genomes. Nature (1984) 1.05
DNA distribution in non-small-cell lung carcinomas and its relationship to clinical behavior. Cytometry (1985) 1.04
Amplification at 7q22 targets cyclin-dependent kinase 6 in T-cell lymphoma. Leukemia (2007) 1.03
Factors influencing the prognostic role of oestrogen and progesterone receptor levels in breast cancer--results of the analysis of 670 patients with 11 years of follow-up. Eur J Cancer (2002) 1.03
Glucose-related protein (GRP78) and its relationship to the drug-resistance proteins P170, GST-pi, LRP56 and angiogenesis in non-small cell lung carcinomas. Anticancer Res (2000) 1.02
Immunomorphological lymph node changes in patients with operable bronchogenic squamous cell carcinoma. Cancer (1977) 1.02
Prognostic significance of DNA patterns and resistance-predictive tests in non-small cell lung carcinoma. Cancer (1985) 1.00
Immunocytochemical detection of a resistance-associated glycoprotein in tissue culture cells, ascites tumors and human tumor xenografts by Mab 265/F4. Anticancer Res (1988) 1.00
Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: a prospective, multicenter phase II study. Ann Oncol (2004) 1.00
Repeated dural punctures increase the incidence of postdural puncture headache. Anesth Analg (1996) 0.99
Phase I/II study of capecitabine and vinorelbine in pretreated patients with metastatic breast cancer. Ann Oncol (2005) 0.99
Homeostatic regulation of CD8+ T cells after antigen challenge in the absence of Fas (CD95). Eur J Immunol (1996) 0.99
International inter- and intrahospital patient spread of a multiple antibiotic-resistant strain of Klebsiella pneumoniae. J Infect Dis (1995) 0.99
MEF2C is activated by multiple mechanisms in a subset of T-acute lymphoblastic leukemia cell lines. Leukemia (2007) 0.99
Cytotoxic T lymphocytes with a grafted recognition specificity for ERBB2-expressing tumor cells. Proc Natl Acad Sci U S A (1994) 0.99
Correlation of DNA flow cytometric results and other prognostic factors in primary breast cancer. Int J Cancer (1988) 0.99
Cleavage of human and mouse cytoskeletal and sarcomeric proteins by human immunodeficiency virus type 1 protease. Actin, desmin, myosin, and tropomyosin. Am J Pathol (1993) 0.98
Phase II study of gemcitabine as first-line chemotherapy in patients with advanced or metastatic breast cancer. Anticancer Drugs (1999) 0.98
Reciprocal correlation between expression of P-glycoprotein and accumulation of rhodamine 123 in human tumors. Anticancer Res (1990) 0.98
[Selective tumour chemotherapy using oncobiograms (author's transl)]. Dtsch Med Wochenschr (1974) 0.97
Karyotypic dissection of Hodgkin's disease cell lines reveals ectopic subtelomeres and ribosomal DNA at sites of multiple jumping translocations and genomic amplification. Leukemia (2000) 0.97
Adhesion induced expression of the serine/threonine kinase Fnk in human macrophages. Oncogene (2000) 0.97
Corticosteroid-induced chemotherapy resistance in urological cancers. Cancer Biol Ther (2006) 0.97